非ST段抬高型急性冠状动脉综合征中的N末端B型利钠肽原

NT-ProBNP in non-ST-elevation acute coronary syndrome.

作者信息

Jernberg Tomas, James Stefan, Lindahl Bertil, Stridsberg Mats, Venge Per, Wallentin Lars

机构信息

Department of Medical Sciences and Cardiology and the Uppsala Clinical Research Center, Sweden

出版信息

J Card Fail. 2005 Jun;11(5 Suppl):S54-8. doi: 10.1016/j.cardfail.2005.04.010.

DOI:10.1016/j.cardfail.2005.04.010

PMID:15948102

Abstract

BACKGROUND

The role of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the early treatment of patients with non-ST-elevation acute coronary syndrome (NSTACS) has been evaluated in 6 large studies that include >12,000 patients.

METHODS AND RESULTS

These studies convincingly show that this marker of cardiac performance is associated strongly with death and the risk of future congestive heart failure and carry important prognostic information that is independent from previous known risk factors in NSTACS. As such, NT-proBNP can be added to existing risk stratification models and multimarker approaches. There is some data that indicate that this marker might also be helpful in guiding decisions about coronary revascularization in these patients, but further studies are needed.

CONCLUSION

Before routine use of NT-proBNP in NSTACS, the extra cost of adding this new marker to the current routine markers and its impact on selection of treatment should be considered.

摘要

背景

六项纳入超过12000例患者的大型研究对N末端脑钠肽前体（NT-proBNP）在非ST段抬高型急性冠状动脉综合征（NSTACS）患者早期治疗中的作用进行了评估。

方法与结果

这些研究令人信服地表明，这种心脏功能标志物与死亡及未来发生充血性心力衰竭的风险密切相关，并携带独立于NSTACS中先前已知危险因素的重要预后信息。因此，NT-proBNP可添加到现有的风险分层模型和多标志物方法中。有一些数据表明，该标志物可能还有助于指导这些患者冠状动脉血运重建的决策，但仍需进一步研究。